Skip to main content

Table 2 Response to maintenance Bevacizumab (mBev) according to activity of Bevacizumab plus Paclitaxel (BT)

From: Maintenance bevacizumab beyond first-line paclitaxel plus bevacizumab in patients with Her2-negative hormone receptor-positive metastatic breast cancer: efficacy in combination with hormonal therapy

 

Response mBev

Activity BT

CR

PR

SD

PD

n

n(%)

n(%)

n(%)

n(%)

4 CR

4 (100)

   

18 PR

 

12 (66.7)

 

6 (33.3)

13 SD

 

1 (7.7)

10 (76.9)

2 (15.4)

  1. mBev, maintenance Bevacizumab; CR, complete response; PR, partial response; SD, stable disease; PD, progression disease.
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us